We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Compass Therapeutics Inc (NASDAQ:CMPX) stands against the other healthcare stocks.
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI. The healthcare sector was a hot topic during the Stargate project announcement, so it is likely that there are going to be even more breakthroughs here as technology advances.
The S&P 500 Healthcare Index trailed the broader market considerably in the past few years. However, it has risen 7% year-to-date so far. There are many promising drugs awaiting approvals and trials right now. As such, healthcare EBITDA is projected to grow at a 7% CAGR, reaching $987 billion by 2028.
The sector is bouncing back from post-pandemic challenges. Nearly 60% of industry leaders expressed a favorable outlook for 2025. Thus, it is worth looking at the healthcare stocks spearheading the gains.
Methodology
For this article, I screened the top-performing healthcare stocks year-to-date. Stocks that I have covered recently will be excluded from this list.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A biopharmacist holding a magnifying glass up against a microscope lens, studying a biological sample.
Compass Therapeutics Inc (NASDAQ:CMPX)
Number of Hedge Fund Holders In Q3 2024: 13
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharma company.
The stock has risen significantly so far in 2025 due to its clinical progress. Phase 2/3 top-line data for biliary tract cancer (BTC) is expected in Q1 2025. Tovecimig (CTX-009) has the potential for accelerated approval.
Moreover, a Phase 2 trial in DLL4-positive colorectal cancer is planned for mid-2025. CTX-8371 also fully enrolled the third cohort for the Phase 1 dose-escalation study; preliminary data is expected in H2 2025.
There is also a new drug candidate called CTX-10726.
The consensus price target of $11.8 implies 281.26% upside.
CMPX stock is up 109.31% year-to-date.
READ NEXT: Why These 15 Industrial Stocks Are Skyrocketing So Far In 2025 and Why These 15 Oil & Gas Stocks Are Skyrocketing So Far In 2025
This article was originally published at Insider Monkey.
Hedge Fund Resource Center